HepaRG culture in tethered spheroids as an in vitro three-dimensional model for drug safety screening

Journal of Applied Toxicology

Volumn 35, Issue 8, 2015, Pages 909-917

  Wang, Zenan ^a,b   Luo, Xiaobei ^a   Anene Nzelu, Chukwuemeka ^c   Yu, Yu ^d   Hong, Xin ^d   Singh, Nisha Hari ^e   Xia, Lei ^d   Liu, Side ^a   Yu, Hanry ^{c,d,e,f,g,h,i}  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g SINGAPORE MIT ALLIANCE   (Singapore)

^h SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

ⁱ Massachusetts Institute of Technology   (United States)

Author keywords

3D in vitro model; CYP induction; Drug safety testing; Galactose; HepaRG; RGD; Xenobiotics

Indexed keywords

ALBUMIN; CHLORPROMAZINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; GALACTOSE; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE A1; KETOCONAZOLE; MESSENGER RNA; PARACETAMOL; ARGINYL-GLYCYL-ASPARTIC ACID; CYTOCHROME P450; OLIGOPEPTIDE;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SAFETY; DRUG SCREENING; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYBRID; IN VITRO STUDY; LIVER CELL; LIVER TOXICITY; MONOLAYER CULTURE; PRIORITY JOURNAL; TETHERED SPHEROID; TUMOR SPHEROID; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL SURVIVAL; CULTURE TECHNIQUE; DRUG EFFECTS; ENZYME INDUCTION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PROCEDURES; TOXIC HEPATITIS; TOXICITY TESTING; TUMOR CELL CULTURE; ULTRASTRUCTURE;

CELL CULTURE TECHNIQUES; CELL SURVIVAL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; ENZYME INDUCTION; GALACTOSE; HEPATOCYTES; HUMANS; MODELS, BIOLOGICAL; OLIGOPEPTIDES; RNA, MESSENGER; SPHEROIDS, CELLULAR; TOXICITY TESTS; TUMOR CELLS, CULTURED;

EID: 84932139982     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.3090     Document Type: Article

References (43)

1. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C, Guillouzo A. 2006. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos. 34: 75-83.
2. Ankley GT, Jensen KM, Kahl MD, Makynen EA, Blake LS, Greene KJ, Johnson RD, Villeneuve DL. 2007. Ketoconazole in the fathead minnow (Pimephales promelas): reproductive toxicity and biological compensation. Environ. Toxicol. Chem. 26: 1214-1223.
3. Anthérieu S, Chesné C, Li R, Camus S, Lahoz A, Picazo L, Turpeinen M, Tolonen A, Uusitalo J, Guguen-Guillouzo C. 2010. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab. Dispos. 38: 516-525.
4. Buchweitz JP, Ganey PE, Bursian SJ, Roth RA. 2002. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J. Pharmacol. Exp. Ther. 300: 460-467.
5. Capezzone de Joannon A, Ceccarini P, Cazzolla N, Milanese C, Rossi V. 2002. Inhibitory Activity on The Human Cytochrome P450 and in vitro Cytotoxic Effects on Human Hepatocytes of Nefazodone. Triazoledione, M-Chlorophenylpiperazine and Trazodone. Pharmacologyonline 3: 77-87.
6. Chang TT, Hughes-Fulford M. 2014. Molecular mechanisms underlying the enhanced functions of three-dimensional hepatocyte aggregates. Biomaterials 35: 2162-2171.
7. Cho CS, Seo SJ, Park IK, Kim SH, Kim TH, Hoshiba T, Harada I, Akaike T. 2006. Galactose-carrying polymers as extracellular matrices for liver tissue engineering. Biomaterials 27: 576-585.
8. Donato MT, Gómez-Lechón MJ, Jover R, Nakamura T, Castell JV. 1998. Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther. 284: 760-767.
9. Gerets HHJ, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, Atienzar FA. 2012. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol. Toxicol. 28: 69-87.
10. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger J. 2013. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch. Toxicol. 87: 1315-1530.
11. Gómez Lechón MJ, Jover R, Donato T, Ponsoda X, Rodriguez C, Stenzel KG, Klocke R, Paul D, Guillén I, Bort R. 1998. Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. J. Cell. Physiol. 177: 553-562.
12. Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA. 2001. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol. 60: 427-431.
13. Goodwin B, Redinbo MR, Kliewer SA. 2002. Regulation of CYP3A Gene Transcription by the Pregnane X Receptor*. Annu. Rev. Pharmacol. Toxicol. 42: 1-23.
14. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. 2007. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168: 66-73.
15. Gunness P, Mueller D, Shevchenko V, Heinzle E, Ingelman-Sundberg M, Noor F. 2013. 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. Toxicol. Sci. 133: 67-78.
16. Harris AJ, Dial SL, Casciano DA. 2004. Comparison of basal gene expression profiles and effects of hepatocarcinogens on gene expression in cultured primary human hepatocytes and HepG2 cells. Mutat. Res. Fundam. Mol. Mech. Mutagen. 549: 79-99.
17. Hegelund T, Ottosson K, Rådinger M, Tomberg P, Celander MC. 2004. Effects of the antifungal imidazole ketoconazole on CYP1A and CYP3A in rainbow trout and killifish. Environ. Toxicol. Chem. 23: 1326-1334.
18. Hoekstra R, Nibourg GAA, van der Hoeven TV, Ackermans MT, Hakvoort T, van Gulik TM, Lamers WH, Elferink RPO, Chamuleau RAFM. 2011. The HepaRG cell line is suitable for bioartificial liver application. Int. J. Biochem. Cell Biol. 43: 1483-1489.
19. Jossé R, Aninat C, Glaise D, Dumont J, Fessard V, Morel F, Poul J-M, Guguen-Guillouzo C, Guillouzo A. 2008. Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab. Dispos. 36: 1111-1118.
20. Kanebratt KP, Andersson TB. 2008a. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 36: 1444-1452.
21. Kanebratt KP, Andersson TB. 2008b. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab. Dispos. 36: 137-145.
22. Klieber S, Torreilles F, Guillou F, Fabre G. 2010. The use of human hepatocytes to investigate drug metabolism and CYP enzyme induction. Methods Mol. Biol. 640: 295-308.
23. Leite SB, Wilk-Zasadna I, Zaldivar JM, Airola E, Reis-Fernandes MA, Mennecozzi M, Guguen-Guillouzo C, Chesne C, Guillou C, Alves PM. 2012. Three-dimensional HepaRG model as an attractive tool for toxicity testing. Toxicol. Sci. 130: 106-116.
24. Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, Silber PM. 1999. Cryopreserved human hepatocytes: characterization of drug-metabolizing activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. 121: 17-35.
25. Livark KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) method. Methods 25: 402-408.
26. Mäkinen J, Frank C, Jyrkkärinne J, Gynther J, Carlberg C, Honkakoski P. 2002. Modulation of mouse and human phenobarbital-responsive enhancer module by nuclear receptors. Mol. Pharmacol. 62: 366-378.
27. McGill MR, Yan HM, Ramachandran A, Murray GJ, Rollins DE, Jaeschke H. 2011. HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity. Hepatology 53: 974-982.
28. Nagaki M, Shidoji Y, Yamada Y, Sugiyama A, Tanaka M, Akaike T, Ohnishi H, Moriwaki H, Muto Y. 1995. Regulation of hepatic genes and liver transcription factors in rat hepatocytes by extracellular matrix. Biochem. Biophys. Res. Commun. 210: 38-43.
29. Rendic S, Carlo FJD. 1997. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29: 413-580.
30. Rodriguez RJ, Buckholz CJ. 2003. Hepatotoxicity of ketoconazole in Sprague-Dawley rats: glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding. Xenobiotica 33: 429-441.
31. Roymans D, Van Looveren C, Leone A, Parker JB, McMillian M, Johnson MD, Koganti A, Gilissen R, Silber P, Mannens G. 2004. Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. Biochem. Pharmacol. 67: 427-437.
32. Scripture CD, Sparreboom A, Figg WD. 2005. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 6: 780-789.
33. Shimada T, Fujii Kuriyama Y. 2004. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and1B1. Cancer Sci. 95: 1-6.
34. Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA. 2004. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab. Dispos. 32: 140-148.
35. Steinberg P, Fischer T, Kiulies S, Biefang K, Platt K-L, Oesch F, Böttger T, Bulitta C, Kempf P, Hengstler J. 1999. Drug metabolizing capacity of cryopreserved human, rat, and mouse liver parenchymal cells in suspension. Drug Metab. Dispos. 27: 1415-1422.
36. Sugimura T, Wakabayashi K, Nakagama H, Nagao M. 2004. Heterocyclic amines: Mutagens/carcinogens produced during cooking of meat and fish. Cancer Sci. 95: 290-299.
37. Szkolnicka D, Farnworth SL, Lucendo-Villarin B, Storck C, Zhou W, Iredale JP, Flint O, Hay DC. 2014. Accurate Prediction of Drug-Induced Liver Injury Using Stem Cell-Derived Populations. Medicine (Baltimore) 3: 1-8.
38. Tzanakakis ES, Hansen LK, Hu W-S. 2001. The role of actin filaments and microtubules in hepatocyte spheroid self-assembly. Cell Motil. Cytoskeleton 48: 175-189.
39. Wang K, Shindoh H, Inoue T, Horii I. 2002. Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in comparison with established cell lines. J. Toxicol. Sci. 27: 229-237.
40. Wells RG. 2008. The role of matrix stiffness in regulating cell behavior. Hepatology 47: 1394-1400.
41. Xia L, Sakban RB, Qu Y, Hong X, Zhang W, Nugraha B, Tong WH, Ananthanarayanan A, Zheng B, Chau IY-Y. 2012. Tethered spheroids as an in vitro hepatocyte model for drug safety screening. Biomaterials 33: 2165-2176.
42. Ying L, Yin C, Zhuo RX, Leong KW, Mao HQ, Kang ET, Neoh KG. 2003. Immobilization of galactose ligands on acrylic acid graft-copolymerized poly (ethylene terephthalate) film and its application to hepatocyte culture. Biomacromolecules 4: 157-165.
43. Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, Chiba K. 2000. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci. 67: 175-184.